{"brief_title": "A Study of Retrovir and Epivir Alone or in Combination With 141W94 in HIV-Infected Patients", "brief_summary": "The purpose of this study is to see if it is safe and effective to add 141W94 to an anti-HIV regimen that includes retrovir plus epivir.", "detailed_description": "This is a double-blind, placebo-controlled, two-arm study comparing treatment with a triple regimen consisting of 141W94, retrovir, and epivir and a double regimen consisting of retrovir and epivir.", "condition": "HIV Infections", "intervention_type": "Drug", "intervention_name": "Zidovudine", "criteria": "Inclusion Criteria Patients must have: - HIV-positive status. - Screening viral load >= 10,000 copies/mm3 14 days prior to entry. - CD4+ cell counts >= 200 cells/mm3 14 days prior to entry. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Clinical diagnosis of AIDS (CDC 1993 Classification C). Concurrent Medication: Excluded: Terfenadine, astemizole, cisapride, triazolam, medazolam, and ergotamine/dihydroergotamine-containing regimens. Patients with the following prior conditions are excluded: Clinically relevant hepatitis in the previous 6 months. Prior Medication: Excluded: - Greater than 4 weeks of any nucleoside antiretroviral therapy. - Previous therapy with an HIV protease inhibitor. - Cytotoxic chemotherapeutic agents within 4 weeks prior to entry. - Immunomodulating agents within 3 months prior to entry. Prior Treatment: Excluded: Radiotherapy within 4 weeks prior to entry. Risk Behavior: Excluded: Current alcohol or illicit drug use that may interfere with the patient's ability to comply with the dosing schedule or protocol evaluations.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00002195.xml"}